Alopecia areata
Methodology & AI Transparency ⓘ
Alopecia areata Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Recognized across U.S.
- 2 Real-world patient consensus: Clinical coding for Alopecia areata uses ICD-10 L63.9 across Hair & Scalp specialty care.
- 3 Typical cash cost range: Workup highlights for Alopecia areata (L63.9): minoxidil growth-phase extension [Alopecia areata L63.9].
- 4 Top reported side effects / signs: Objective lab/clinical target for Alopecia areata: Total/Free Testosterone & in Alopecia areata (L63.9: DHEA-S (if androgenic)) (Age/sex physiological range (L63.9)) and Serum Ferritin [Alopecia areata L63.9].
Ask our AI Specialists anything about Alopecia areata
What Is Alopecia areata?
Recognized across U.S. clinical coding as L63.9 (Hair & Scalp), Alopecia areata is evaluated via minoxidil growth-phase extension [Alopecia areata L63.9] to align day-to-day symptom relief with long-term physiological stability.
Pathophysiology, Underlying Causes & Clinical Presentation
At the cellular and tissue level in hair & scalp, Alopecia areata (L63.9) involves perifollicular autoimmune lymphocytic in Alopecia areata (L63.9: attack (alopecia areata)). progression correlates with shifts in Total/Free Testosterone & in Alopecia areata (L63.9: DHEA-S (if androgenic)) (Age/sex physiological range (L63.9)).
Common Symptoms & Clinical Signs
- • Presentation of Alopecia areata (L63.9): thickened, discolored, brittle, in Alopecia areata (L63.9: or subungually lifting)
- • Secondary Alopecia areata clinical sign: gradual widening of in Alopecia areata (L63.9: the central scalp)
- • Symptom flares in Alopecia areata correlating with Total/Free Testosterone & in Alopecia areata (L63.9: DHEA-S (if androgenic)) deviation outside Age/sex physiological range (L63.9)
- • Functional hair & scalp impact requiring minoxidil growth-phase extension [Alopecia areata L63.9] evaluation (L63.9)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Alopecia areata Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | L63.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Hair Loss, Alopecia & Scalp Conditions | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Total/Free Testosterone & in Alopecia areata (L63.9: DHEA-S (if androgenic)) | Age/sex physiological range (L63.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Ferritin [Alopecia areata L63.9] | 70 – 150 ng/mL (L63.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: TSH & Free in Alopecia areata (L63.9: T4) | TSH 0.8 – 2.5 mIU/L (L63.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Alopecia areata
Treatment selection for Alopecia areata depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Alopecia areata)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Efficacy comparison of monotherapies and combination therapies for androgenetic: What a 3,133-Participant Study Found In recent years, combination therapies are showing significant promise as potential therapies. Dermatologic therapy • 2022-03-15 • Meta-Analysis | N = 3,133 | 99/100 | PMID 34897933 ↗ |
| New Insights on Combination Therapy in Androgenetic hair loss: A Network Meta-Analysis of: What a 3,012-Participant Study Found Based on the current studies, we found that the combination of Minoxidil with spironolactone, PRPF, flutamide, and finasteride may offer better treatment outcomes for patients with androgenetic hair loss. Aesthetic plastic surgery • 2026-07-15 • Meta-Analysis | N = 3,012 | 99/100 | PMID 42168420 ↗ |
| New Insights on Glycolipid and Hormonal Profiles in Young Men with Early-Onset Androgenetic hair: What a 1,009-Participant Study Found The acknowledgement of this syndrome would be of importance to prevent the long-term consequences on health in the affected men. Scientific reports • 2017-08-10 • Meta-Analysis | N = 1,009 | 94/100 | PMID 28798373 ↗ |
| New Insights on Bilateral Association Between eczema® and hair loss: What a 233,448-Participant Study Found Based on 7 studies, there was a significant association between AD and AA when AA was the exposure factor [odds ratio, OR, = 4.537 (95% CI: 2.409-8.544)]; based on 10 studies, there was also a significant association between... Dermatitis : contact, atopic, occupational, drug • 2024-01-15 • Meta-Analysis | N = 233,448 | 94/100 | PMID 37471232 ↗ |
| New Insights on Treatments for hair loss: What a 3,149-Participant Study Found Even with the network meta-analysis, the best treatment because of independent loops and wide confidence intervals could not be identified. Dermatologic therapy • 2021-05-15 • Meta-Analysis | N = 3,149 | 94/100 | PMID 33631058 ↗ |
Alopecia areata Patient Community & “People Like Me” Threads
Filter Alopecia areata community threads and patient logs by age, biological sex, dosage, and treatment duration.